徐斌 余英豪 郑曦 吴钦穗
[摘要] 目的 分析基因多态性与乳腺癌易感性及临床病理特征,为乳腺癌的治疗提供依据。方法 2007年1月—2011年2月,方便收集200例乳腺浸润癌患者存档病例,进行组织ER、PR、HER-2、CK5/6、EGFR检测,根据乳腺癌组织免疫组化检测及FISH方法检测HER-2基因扩增状况并按照Nielsen标准进行乳腺癌基因分型。结果 不同基因分型的CD117阳性、年龄、肿块直径、组织学分级、腋窝淋巴结转移、TNM分期存在差异,HER-2(+)占CD117阳性69.2%(9/13)。结论 基底细胞型、CD117阳性会增加三阴乳腺癌风险,预后相对更差。
[关键词] 乳腺癌;基因多态性;临床病理
[中图分类号] R5 [文献标识码] A [文章编号] 1674-0742(2018)02(a)-0029-03
Genetic Polymorphism and Susceptibility to Breast Cancer and Its Clinicopathological Characteristics
XU Bin1, YU Ying-hao2, ZHENG Xi1, WU Qin-sui1
1.Pathology Department, the First Hospital of Fuzhou, Fuzhou, Fujian Province, 350009 China; 2. Pathology Department, Fuzhou General Hospital of the Liberation Army, Fuzhou, Fujian Province, 350025 China
[Abstract] Objective This paper tries to analyze the gene polymorphism and susceptibility of breast cancer and clinical pathological features, and to provide the basis for the treatment of breast cancer. Methods 200 cases of invasive breast cancer from January 2007 to February 2011 were convenient selected, ER, PR, HER-2, CK5/6, EGFR detection were carried out, according to the immunohistochemical detection of breast cancer and the FISH method for detection of HER-2 gene amplification and genotyping of breast cancer according to the Nielsen standard. Results The CD117 of different genotypes positive, age, tumor size, histological grade, axillary lymph node metastasis and TNM staging were different. HER-2(+) accounted for 69.2%(9/13) of CD117 positive. Conclusion Basal cell type, CD117 positive will increase the risk of three negative breast cancer, and the prognosis is worse than that of TNM
[Key words] Breast cancer; Gene polymorphism; Clinical Pathology
乳腺癌简称乳癌,又称乳房癌,99%的乳腺癌是女性,在发达国家,乳腺癌已成为女性三大恶性肿瘤之一[1]。在我国,乳腺癌整体发病率低于发达国家,但因经济的发展、生活习惯的改变,发病率快速上升,在一线城市发病率接近发达国家,年发病率约为12/10万,患者趋于年轻化[2]。基因多态性分析在恶性肿瘤诊治中越来越受到重视,对于乳腺癌而言,其存在明显的家族病史,不同患者的疗效存在较大的差异,三阴乳腺癌预后相对较差,分析基因多态性特征,对于乳腺癌的预防、诊断、治疗有重要意义[3-4]。该次研究尝试,以2007年1月—2011年2月期间约200例乳腺浸润癌患者存档病例,进行基因检测、病理分析,现报道如下。
1 资料与方法
1.1 一般资料
方便收集200例乳腺浸润癌患者存档病例。纳入标准:①所有患者均为女性;②临床资料完整;③术前均未做化疗、免疫或放射治疗。收集的档案均不调取个人的社会人口信息,而仅入选临床信息,调用数据经过伦理委员会批准。……